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Characterization of the role of TMEM45A in cancer
cell sensitivity to cisplatin
Kathleen Schmit1, Jia-Wei Chen1, Sophie Ayama-Canden1, Maude Fransolet1, Laure Finet2, Catherine Demazy1,
Lionel D’Hondt2, Carlos Graux2 and Carine Michiels1
Abstract
TMEM45A is a transmembrane protein involved in tumor progression and cancer resistance to chemotherapeutic
agents in hypoxic condition. It is correlated to a low breast cancer patient overall survival. However, little is known
about this protein, in particular the mechanisms by which TMEM45A modulates cancer cell chemosensitivity. In this
work, the messenger RNA expression of TMEM45A was assessed in head and neck squamous cell carcinoma (HNSCC)
and renal cell carcinoma (RCC) biopsies. TMEM45A was upregulated in patients diagnosed for head and neck or renal
cancer. Then, the implication of this protein in cisplatin sensitivity was explored in SQD9 and RCC4+ pVHL cells.
TMEM45A inactivation decreased cell proliferation and modulated cell responses to cisplatin. Indeed, TMEM45A
inactivation increased the sensitivity of SQD9 cells to cisplatin, whereas it rendered RCC4+ pVHL cells resistant to this
anticancer agent. Through RNA-sequencing analysis, we identified several deregulated pathways that indicated that
the impact on cisplatin sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway
activation. This study demonstrated, for the first time, an anti or a pro-apoptotic role of this protein depending on the
cancer type and highlighted the role of TMEM45A in modulating patient responses to treatment.
Introduction
Renal cell carcinoma (RCC) and head and neck squa-
mous cell carcinoma (HNSCC) constitute two of the ten
most common cancers1,2. International Agency for
Research on Cancer recorded >350,000 new cases of
HNSCC worldwide in 2018, with 25% of oral cancer being
HPV-positive3. The current standard treatments for this
disease are surgery, radiotherapy, and chemotherapy. The
four most extensively used agents are methotrexate, cis-
platin, 5-fluorouracil (5-FU), and bleomycin. Over the
years, significant advances have been made in combined
modality therapies but the majority of patients who pre-
sent advanced disease relapse still develop metastases and
only qualify for palliative treatment4.
Human RCCs are classified in subtypes with the most
common being clear cell RCC (ccRCC), which represents
75–80% of the group5. von Hippel-Lindau (VHL) tumor
suppressor gene is the most frequently mutated gene6,7.
ccRCC can be treated by surgical excision or with ablative
therapies, but also with systemic therapies. The most used
drugs are angiogenesis targeting agents, including sor-
afenib, sunitinib, and bevacizumab, which target vascular
endothelial growth factor (VEGF) or its receptor
(VEGFR). Despite all the therapeutic targeting agents
discovered during the last decade, many patients are
resistant to these treatments or acquire resistance over
time8,9. Furthermore, due to the ability of the kidney to
functionally compensate when partially damaged10, most
patients are diagnosed with advanced or metastatic RCC.
Transmembrane protein family (TMEMs) is a family of
proteins predicted to be components of various cell
membranes, such as mitochondrial, endoplasmic reticu-
lum, and golgi membranes. In many cancers, differential
expression of TMEMs is observed and a large number of
these proteins have been implicated in cancer develop-
ment and drug resistance11.
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TMEM45A is a transmembrane protein of 275 amino
acids, predicted to have five or seven transmembrane
domains and which is upregulated in hypoxic condition.
This protein is highly expressed in the skin, is associated
with trans-golgi apparatus and whose expression is cor-
related with epiderm keratinization12–14. TMEM45A has
been proposed as a potential classifier of ccRCC15, but
was also associated with chemoresistance in human breast
cancer cells and in human hepatoma cells in hypoxic
condition16. TMEM45A affects proliferation and invasion
in human ovarian cancer cells and in human glioma
cells17,18. In the cases of breast cancer and cervical lesions,
higher expression level of TMEM45A has been correlated
with lower patient overall survival, suggesting that
TMEM45A could be a potential biomarker for
aggressiveness16,19.
Since the expression of this protein has been associated
with tumor aggressiveness, we studied the possible role of
TMEM45A in cancer resistance to chemotherapies and
the mechanism by which it acts. The effect of TMEM45A
inactivation was investigated on responses to cisplatin in
head and neck and renal cancer cells in normoxic and
hypoxic conditions. Our data support an implication of
TMEM45A in the sensitivity of cancer cells to cisplatin.
Materials and methods
Patient study
After written informed consent of patients (Biobank
CHU-UCL Namur, Belgium), healthy tissues, which were
histologically free from tumor and head and neck and
renal cancer biopsies, were obtained from surgery. The
Medical Ethical Committee of CHU-UCL Namur
approved all described studies. After resection, the sam-
ples were stored at −80 °C and messenger RNA (mRNA)
were extracted as described below. Primary tumor speci-
mens and paired noncancerous tissues were obtained
from 22 patients who were diagnosed with HNSCC. The
ORL specimens analyzed in this study were obtained from
patients of both gender with HNSCC, who were diag-
nosed between August 2010 and April 2018. The age of
patients ranged from 43 to 77 years, with a median age of
57 years. Primary tumor specimens and paired non-
cancerous tissues were obtained from 25 patients who
were diagnosed with RCC. The renal specimens analyzed
in this study were obtained from patients of both gender
with RCC, who were diagnosed between October 2011
and October 2015. The age of patients ranged from 43 to
91 years, with a median age of 67 years.
TCGA analysis of samples from human tumors and
corresponding healthy tissues were performed for five
cancer types: ESCA: esophageal carcinoma, HNSC: head
and neck squamous carcinoma, KICH, kidney chromo-
phobe, KIRC, kidney renal clear cell carcinoma, KIRP
kidney renal papillary cell carcinoma (http://gepia.cancer-
pku.cn/detail.php?gene=TMEM45A&clicktag= expdiy).
Cell culture
Head and neck squamous cell carcinoma cell lines
(SQD9 and Cal 27) were obtained from Pierre Sonveaux
laboratory, Woluwe, Belgium and maintained in culture in
75 cm2 polystyrene flasks (Corning) in Minimum Essen-
tial Media (MEM) (Thermo Fisher Scientific) supple-
mented with 10% of heat inactivated fetal bovine serum
(FBS) (Thermo Fisher Scientific). Renal cell carcinoma
cell line RCC4 stably transfected with pcDNA3-VHL
(RCC4 plus pVHL) was purchased from the European
Collection of Authenticated Cell Cultures (Sigma-
Aldrich) and maintained in culture in 75 cm2 polystyrene
flasks (Corning) in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Thermo Fisher Scientific) supplemented with
2 mM of L-glutamine (Sigma-Aldrich), 10% of fetal bovine
serum (FBS) (Thermo Fisher Scientific), and geneticin
(0.5 mg/mL) (Thermo Fisher Scientific). Cells were incu-
bated under an atmosphere at 37 °C containing 5% CO2.
The cell cultures were tested for mycoplasms every
3 months and were shown to be always negative.
Incubation and hypoxia incubation
Cisplatin (Sigma-Aldrich) was dissolved in NaCl 0.9%
before each experiment then directly added in the culture
medium without serum. All experiment was performed in
serum-free CO2-independent medium (Thermo Fisher
Scientific) supplemented with 500 μM of L-glutamine
(Sigma- Aldrich), except for DNA damage repair experi-
ment for which fresh culture medium with serum was
added to the cells after cisplatin incubation. For hypoxia
experiments, cells were incubated under 1% O2, whereas
for normoxic conditions cells were incubated under
normal atmosphere (20% O2).
Transfection and transduction
For transfection, SQD9 cells were seeded in 75 cm2
polystyrene flasks (Corning) at a density of 3,000,000 cells
per flask. TMEM45A knockdown was achieved using
siGENOMESMART pool human TMEM45A (#M-
021085-00 containing a mix of four siRNA: CAAUGUA
CUUCUGGAGCUA, GGGAAAUGCUGGACAUCUU,
AAGCGAACCUGCUAUCUUG, UAAACAAGGUCACU
GGAAU from Dharmacon). RISC-free control siRNA
purchased from Dharmacon was used as a control for
non-specific effects. Cells were transfected 24 h under
standard culture conditions with 50 nM siRNA using
DharmaFect no. 1 (Dharmacon) transfection reagent
according to the manufacturer’s instructions. Cells were
then trypsinized and seeded at the appropriate density for
further experiments.
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For the transduction, cells were seeded in 25 cm2
polystyrene flasks (Corning) at a density of 800,000 cells
per flask. Cells were then transduced with short-hairpin
RNA (shRNA) lentiviral particles (Sigma): empty vector as
a control for RCC4 cells and shRNA targeting the luci-
ferase (CCGGCGCTGAGTACTTCGAAATGTCCTCGA
GGACATTTCGAAGTACTCAGCGTTTTT) as negative
control for SQD9 cells (shCTL) or shRNA targeting
TMEM45A mRNA, shRNA22 (CCGGGAGTTCCTTGT
TCGGAACAATCTCGAGATTGTTCCGAACAAGGAA
CTCTTTTTTG) and shRNA 92 (CCGGGATGACTCTA
AGTGTACTGTTCTCGAGAACAGTACACTTAGAGT
CATCTTTTTTG). The transduction was performed with
a multiplicity of infection (MOI) of 5 in fresh medium
with serum containing protamine sulfate (0.06 mg/mL)
(Sigma-Aldrich) for RCC4 cells. Twenty-four hours after
the transduction, the medium was replaced by fresh
medium supplemented with puromycin (4 μg/mL)
(Sigma-Aldrich) for 6 days of selection. After the selec-
tion, cells were seeded in 75 cm2 polystyrene flasks
(Corning) with medium without puromycin and used for
further experiments.
RNA sequencing
Sample preparation
SQD9 cells, untreated or treated with 20 µM of cisplatin
for 24 h, were collected and lysed in RLT Lysis Buffer
(Qiagen). Total RNA was extracted using the RNeasy
Mini Kit (Qiagen) and the automation QIAcube (Qiagen).
The analysis was performed for four biological indepen-
dent experiments. The quality and integrity of the RNA
samples was checked using the Bioanalyser 2100 (Agi-
lent). Samples were sent to Genomics core (KU Leuven)
for sequencing: a paired-end (PE) library was constructed
using TruSeq RNA Library Prep Kit v2 (Illumina). A gene
level single-read sequencing was performed on Illumina’s
HiSeq 2500 platform (short read 50-SR50).
Data analysis
Bioinformatics Consultancy Service of Genomic core
performed the data analysis.
Mapping and differential expression (DE): quality control
of raw reads was performed with FastQC v0.11.5 and
adapters were filtered with ea-utils v1.2.2.18. The QC
made using FastQC permits to determine the GC
content of all reads and the sequencing quality base per
base. Splice-aware alignment was performed with
TopHat v2.0.13 against the human reference genome
GRCh37/hg19 (http://hgdownload.soe.ucsc.edu/
downloads.html#human) with the following parameters:
two allowed mismatches, reads that mapped to more
than one site to the reference genome discarded and a
minimal score of alignment quality included in count
analysis of 10.
Gene count and differential expression: resulting SAM
and BAM alignment files were handled with Samtools
v0.1.19.24. Quantification of reads per gene was
performed with HT-Seq count v0.5.3p3. Count-based
differential expression analysis was done with R-based
(The R Foundation for Statistical Computing, Vienna,
Austria) Bioconductor package DESeq. DESeq is a
method based on negative binomial distribution model-
ing, that improves the specificity and sensitivities, as well
as good control of false-positive errors, taking into
account gene length for the counting (https://support.
bioconductor.org/p/74572/). Reported p-values were
adjusted for multiple testing with the
Benjamini–Hochberg procedure, which controls false
discovery rate (FDR) and differentially expressed genes
were selected at a FDR 0.1.
Gene ontology analysis: gene set enrichment analysis
(GSEA-http://software.broadinstitute.org/gsea/msigdb/
index.jsp) was performed from count files obtain with
HT-Seq count. C5 collection was used to analyze the
count datas. The gene sets in the C5 collection are based
on GO terms (go-basic.obo, downloaded on 3 May,
2016) and their associations to human genes (gene2go,
downloaded from NCBI FTP server on 3 May, 2016). GO
are divided in three types: molecular function (MF),
cellular component (CC), or biological process (BP).
(Jaccard’s coefficient > 0.85-http://geneontology.org/
page/guide-go-evidence-codes). Panther (http://www.
pantherdb.org/) and Babelomics (http://babelomics.
bioinfo.cipf.es/) Gene ontology were used to identify
pathways involved from differentially expressed gene
lists, selected using an FDR of 0.1. The results obtained
were compared to highlight the most relevant pathways/
genes of interest.
The RNAseq data were made available: experiment can
be viewed in ArrayExpress under this link: https://www.
ebi.ac.uk/arrayexpress/experiments/E-MTAB-7518
Real-time quantitative polymerase chain reaction (RT-
qPCR)
For patient biopsies, samples were lyzed in Qiazol
reagent. After 5 min at room temperature, 200 μL of
chloroform were added and the samples were shacked
vigorously for 2–3min. After centrifugation at 12,000 x g
for 15 min at 4 °C, the upper aqueous phase was trans-
ferred to a new tube and the total RNA was extracted
using the RNeasy Mini Kit (Qiagen) and the QIAcube
(Qiagen). For the amplification complementary DNA
(cDNA) was diluted at 1:100 in MilliQ water and added to
the mix reaction containing 300 nM of forward and
reverse primers (Table 1) and SYBR Select Master Mix
(Thermo Fisher Scientific) in a 5 to 1 ratio. qPCR was
conducted on a StepOnePlus system (Applied Biosystems)
following thermal cycling: 95 °C for 5 min followed by 40
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cycles at 95 °C for 30 s and 60 °C for 1 min. mRNA
expression level was quantified using the threshold cycle
method, given the fold change (FC): downregulated genes
with a FC < 0.5 and upregulated genes with a FC > 1.5.
For cells samples, after the incubation, 600 μL of RLT
Lysis Buffer (Qiagen) was added to lyse the cells. Total
RNA was extracted using the RNeasy Mini Kit (Qiagen)
and the QIAcube (Qiagen). mRNA contained in 2 μg of
total RNA was reverse transcribed using first Strand
cDNA Synthesis kit (Roche Life Science) following sup-
plier’s instructions. For the amplification cDNA was
diluted at 1:100 in MilliQ water and added to the mix
reaction containing 300 nM of forward and reverse pri-
mers (Table 1) and SYBR Select Master Mix (Thermo
Fisher Scientific) in a 5 to 1 ratio. qPCR was conducted on
a StepOnePlus system (Applied Biosystems) following
thermal cycling: 95 °C for 5 min followed by 40 cycles at
95 °C for 30 s and 60 °C for 1 min. mRNA expression level
was quantified using the threshold cycle method. The
experiment was performed for 3 biological independent
experiments.
Western blot
After the incubation, cells were lysed in lysis buffer
solution containing Trizma 40 mM (TRIS base) (Sigma-
Aldrich), KCL 150mM (Merck Millipore) and Tritriplex
III 1 mM (Merck Millipore) with MilliQ water, Triton
X100 1% (Sigma-Aldrich), phosphatase inhibitor cocktail
(PIC, Roche), and phosphatase inhibitor buffer (PIB
containing sodium orthovanadate (Na3VO3) (Sigma-
Aldrich), 4-nitrophenylphosphate (PNPP) (Sigma-
Aldrich), β-glycerophosphate (VWR) and sodium fluoride
(NaF) (Merck)). Then 15 μg of proteins were mixed with
MilliQ water and blue sample buffer composed of DTT
(dithiothreitol) 5% and LDS (lithium dodecyl sulfate)
sample buffer 4 × (Thermo Fisher Buffer) and heated up
during 10min to 70 °C. Proteins were then separated on
NuPAGE 4–12% Bis-Tris Gel or 3–8% Tris Acetate Gel
(Thermo Fisher Scientific). Afterwards, proteins were
transferred on a PVDF (polyvinylidene fluoride) mem-
brane (Thermo Fisher Scientific). The membrane was
incubated overnight at 4 °C with the primary antibody
(Table 2) in Odyssey Blocking buffer (Li-Cor Biosciences)
with 0.1% of Tween 20 (Bio-Rad Laboratories) and incu-
bated with the secondary antibody during 1 h in Odyssey
Blocking buffer (Li-Cor) with 0.1% of Tween 20 (Bio-Rad
Laboratories). The membrane was scanned using the
Odyssey Infrared Imager (Li-Cor Biosciences). The
fluorescence was quantified using the imaging software
Odyssey V3.0 from the Odyssey Infrared Imager (Li-Cor
Biosciences).
MTT
After incubation, MTT (Thiazol Blue Tetrazolium
Bromide) (Sigma-Aldrich) was diluted in PBS at 2.5 mg/
mL and added to cell media for 2 h at 37 °C. Afterwards,
cells were lysed with a lysis buffer composed of sodium
dodecyl sulfate (SDS) 30% (Merck Millipore) and N, N-
dimethylformamide (Sigma- Aldrich) in a 2 to 1 ratio at
pH 4.7 during an hour at 37 °C. Finally, the optic density
was read with a spectrophotometer at 570 nm.
Caspase 3/7 activity
After incubation, the cells were lysed with a lysis buffer
containing HEPES 20 mM (Sigma-Aldrich), Tritriplex III
4 mM (Merck Millipore), CHAPS 0.2% (3-[(3-cholami-
dopropyl)dimethylammonio]-1-propanesulfonate
hydrate) (Sigma-Aldrich), sucrose 300mM, DTT 1M
(Sigma-Aldrich), and MilliQ water. Then, reaction buffer
composed of PIPES (1,4-Piperazinediethanesulfonic acid)
40mM (Sigma-Aldrich), NaCl 200 mM (Merck Milli-
pore), Tritriplex III 2 mM (Merck Millipore), CHAPS
Table 1 Primers used for qPCR and PCR.
Genes Firm Forward primer Reverse primer
23 kDa Integrated DNA Technologies GCCTACAAGAAAGTTTGCCTATCTG TGAGCTGTTTCTTCTTCCGGTAGT
ATF6B Integrated DNA Technologies AGAGTCCCTGTCCCCTTCAG ACTACAGGTTTGGGCTGCAG
CAIX Integrated DNA Technologies GAGGCCTGGCCGTGTTG AACTGCTCATAGGCACTGTTTTCTT
Calreticulin Integrated DNA Technologies CACCAACGATGAGGCATACG TTTGTTTCTCTGCTGCCTTTGTTAC
EYA3 Integrated DNA Technologies AGCCATGGTTCATCTGTGGG CAGTGCTTCCTTCCTCTGGG
HSP90B1 Integrated DNA Technologies TCATCCAACTGACATTACTAGCC ACAAATGGAGAAGATTCAGCCTC
MANF Integrated DNA Technologies ACCAGGACCTCAAAGACAGAG CATTGATGATTTTGGTGGCTGC
PDIA6 Integrated DNA Technologies GAAGATGTTTGGATGGTTGAGTTCT TAGCATCCACAGCTGCCAGTT
TMEM45A Integrated DNA Technologies TTATGCAGTAACCATTGTCATCGTT TGATTCTTGTTCTCGTTCAGCATT
XBP1 Integrated DNA Technologies GATGGATGCCCTGGTTGCT TGAAGAGTCAATACCGCCAGA
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0.2% (Sigma-Aldrich), sucrose 300 mM, DTT 1M (Sigma-
Aldrich) was added to the lysis solution containing 15 μg
of proteins. The fluorogenic substrate Ac-DEVD-AFC
(BD Pharmingen) was used to measure caspase 3 and 7
activity. Fluorescence intensity was measured using a
spectrophotometer at 400 nm for excitation and 505 nm
for emission.
LDH release
After the incubation, the supernatant of each well was
collected in 1.5 mL microtubes labeled as “Pellet”. Two-
hundred fifty microliters of PBS-Triton 4% were added in
each well and plates were left at room temperature with a
slight agitation during 10 min. The “Pellet” microtubes
were centrifuged during 5min at 2000 rpm at 4 °C. The
supernatant of the “Pellet” microtubes was then trans-
ferred into microtubes called “Supernatant” while the
pellets were resuspended in 250 μL of PBS-Triton 4%. The
cell lysate in the wells of the plates was collected in a third
series of microtubes labeled as “Lysate”.
One-hundred microliters of each sample were placed in
a 96-well plate, except for the “Lysate” samples of which
5 μL were diluted in 95 μL of PBS-Triton 4%. One-
hundred microliters of Cytotoxicity Detection Kit (Roche)
were added in each well and after 15 min of reaction, the
optic density was read with a spectrophotometer at
490 nm and 655 nm every 15min until at least one value
reached 2. The signal obtained at 655 nm was subtracted
of the signal obtained at 490 nm and the percentage of
cytotoxicity was then calculated as follows:
% cytotoxicity ¼
Pellet Blankð Þ þ Supernatant  Blankð Þ  4ð Þ
Pellet Blankð Þ þ Supernatant  Blankð Þ  4ð Þ þ Lysate Blankð Þ  20ð Þ
Table 2 Antibodies used for immunofluorescence labeling and western blot.
Protein Primary antibody Secondary antibody
Immunofluorescence labeling
TMEM45A Anti-TMEM45A
(Rabbit, Sigma HPA024082, 1/250)
Alexa 488 nm
(Anti-rabbit, Thermo Fisher Scientific A-11008, 1/1000)
Golgin-97 Anti-Golgin-97
(Mouse, Thermo Fisher Scientific A-21270, 1/400)
Alexa 568 nm
(Anti-mouse, Thermo Fisher Scientific, A-11004, 1/1000)
GM130 Anti-GM130
(Mouse, BD Biosciences 610823, 1/250)
Alexa 568 nm
(Anti-mouse, Thermo Fisher Scientific, A-11004, 1/1000)
RAD51 Anti-RAD51
(Rabbit, Sigma HPA024012, 1/400
Alexa 488 nm
(Anti-rabbit, Thermo Fisher Scientific A-11008, 1/1000)
H2AX Anti-Phospho Histone H2A.X S139
(Rabbit, Cell Signaling #2577S, 1/200)
Alexa 488 nm
(Anti-rabbit, Thermo Fisher Scientific A-11008, 1/1000)
Western blot
PARP Anti-PARP
(Mouse, BD Biosciences 6639GR, 1/2000)
IRDye 680RD
(Anti-mouse, Li-Cor Biosciences 926–68070, 1/10,000)
Caspase 3 Anti-Caspase 3
(Rabbit, Cell Signaling #9662S, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
H2AX Anti-Phospho Histone H2A.X S139
(Rabbit, Cell Signaling #2577S, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
ATM/ATR substrate Anti-Phospho ATM/ATR substrate S*Q
(Rabbit, Cell Signaling #9607, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
EYA3 Anti-EYA3
(Rabbit, Abcam, ab129501, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
IRE1α total Anti-IRE1α
(Rabbit, Novus bilogicals, NB100-2324, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
Phospho IRE1α Anti-IRE1α Phospho S724
(Rabbit, Abcam, ab124945, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926–32211, 1/10,000)
β-actin Anti-β-Actin
(Mouse, Sigma-Aldrich A5441, 1/10,000)
IRDye 680RD
(Anti-mouse, Li-Cor Biosciences 926–68070, 1/10,000)
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Immunofluorescence labeling
Cells were seeded on glass coverslips in 24-well plates
(Costar) at a density of 25,000 cells per well. After the
incubation time, the medium was removed and cells were
then fixed during 10 min with 4% paraformaldehyde
(PFA) in phosphate buffer saline (PBS) before being
washed three times with PBS and permeabilized with
PBS-triton 1% for 5 min at room temperature. After
permeabilization, cells were washed three times for
10min with PBS-BSA 2% (Bovine Serum Albumin) (Santa
Cruz Biotechnology) then incubated with the primary
antibody overnight at 4 °C in the dark (Table 2). The next
day, cells were washed three times with PBS-BSA 2%
before being incubated for 1 h with the secondary anti-
body and Hoechst (Thermo Fisher Scientific H-21491) at
2 μg/mL at room temperature in the dark. Thereafter,
cells were washed three times with PBS-BSA 2% and once
with PBS. The coverslips were finally mounted on slides in
Mowiol mounting solution (Sigma) warmed at 57 °C.
Slides were observed by confocal microscopy (SP5, Leica).
Statistical analysis
Prism software was used for the generation of all sta-
tistical analyses. Paired T-test with two tailed p-value was
used for the Fig. 1. Two-way ANOVA and multiple
comparisons were used for all other figures. p < 0.05 was
considered statistically significant. The variance was tes-
ted with Prism for all experiments and shown to be
similar between the groups within one experiments. For
consistency in these comparisons, the following identifies
the significance values: *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. All results are presented from at least three
independent replicates.
Results
TMEM45A expression in HNSCC and ccRCC human biopsies
To explore TMEM45A expression in human samples of
HNSCC or ccRCC patients, TMEM45A mRNA level was
evaluated by RT-qPCR in tumor samples and corre-
sponding adjacent healthy tissues for each patient.
TMEM45A transcript was upregulated in tumor tissues
compared to healthy tissues in 86% (19/22) and 76% (19/
25) of HNSCC and ccRCC samples respectively (Fig. 1a, b).
Furthermore, TCGA analysis showed that TMEM45A
expression was significantly higher in HNSCC and ccRCC
human tumors than in corresponding healthy tissues
(Fig. 1c). TMEM45A is upregulated in hypoxic conditions
under the control of the transcription factor HIF1 (hypoxia
inducible factor 1)12. Furthermore, in normoxic condi-
tions, HIF1α stability is regulated by pVHL. Since pVHL is
mutated in ccRCC, HIF1α is no longer degraded, hence
conferring a state of pseudo-hypoxia20. It has to be noted
that, in most studies, HIF1 was shown to suppress while
HIF2 was shown to promote tumor growth. In order to
sought whether HIF1 was activated in these samples, we
analyzed the expression of a second HIF1 target gene,
CAIX (Carbonic Anhydrase IX). All HNSCC samples,
which displayed TMEM45A overexpression also presented
CAIX upregulation. For ccRCC, 9 samples out of
10 showed the same expression profiles for TMEM45A
and CAIX (Fig. 1d, e). These data revealed that TMEM45A
is upregulated in a majority of patients with HNSCC and
ccRCC and that this upregulation is probably under the
control of HIF1.
Identification of deregulated genes and associated
signaling pathways in TMEM45A-inactivated cells
In order to investigate the role of TMEM45A in cancer
cell chemoresistance, cisplatin sensitivity was determined
for different cancer cell lines: SQD9 cells for HNSCC and
RCC4+ pVHL for ccRCC. Cisplatin is a chemother-
apeutic drug inducing DNA damage during cell replica-
tion, leading to cell death by apoptosis21. The IC50 was
reached after incubation with 100 μM for 24 h for SQD9
cells and with 20 μM for 48 h for RCC4+ pVHL cells
(Supplementary Fig. 1). These conditions were thus used
for the next experiments. Then, to explore the functions
of TMEM45A, its expression was inactivated using siRNA
or shRNA strategies. A strong decrease in both
TMEM45A mRNA and protein levels was observed in
both cell lines for both inactivation strategies (Supple-
mentary Fig. 2). TMEM45A inactivation was associated
with the presence of large vesicles in SQD9 cells (Fig. 2a,
b), whereas no change in morphology was observed for
RCC4+ pVHL cells (Fig. 2c).
In order to identify putative pathways deregulated upon
TMEM45A inactivation, a transcriptome analysis by RNA
sequencing was performed in SQD9 cells. Two-hundred
sixty-three differentially expressed genes were identified
in the absence of cisplatin and 469 differentially expressed
genes were identified in the presence of cisplatin (Fig. 2d).
Unsurprisingly, the most downregulated gene in cells
incubated without cisplatin was TMEM45A, with a fold
change of 0.2. Another interesting gene was POLDIP2.
POLDIP2 has been shown to regulate in DNA polymerase
activation22 and to be an oxygen-sensitive protein23,24.
Furthermore, POLDIP2 has been implicated in tumor
growth and invasiveness in non-small cell lung cancer25.
All these data made of POLDIP2 a good candidate for
further investigation but the difference observed in
mRNA expression was not confirmed at protein level
(data not shown).
In order to identify pathways affected by TMEM45A
knockdown, bioinformatic analysis using Babelomics
analysis and Gene Set Enrichment Analysis (GSEA) was
performed. Then, heatmaps of differentially expressed
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genes for these pathways were generated using Heat-
mapper26. Several pathways appeared to be deregulated
such as the G2/M transition pathway (Supplementary Fig.
3 and Fig. 2e). In parallel, a decrease of about 30% in the
proliferation rate for both SQD9 and RCC4+ pVHL cells
was observed in the knockdown cells compared to control
cells (Fig. 2f, g). This decrease in proliferation is probably
due to a delay in cell cycle progression since an accu-
mulation of cells in S phase was detected (Supplementary
Fig. 5). These data indicate a role of TMEM45A in the
regulation of cell proliferation.
TMEM45A inactivation impacts the sensitivity to cisplatin
Several deregulated pathways in TMEM45A knock-
down cells were related to apoptosis (Supplementary Fig.
3). To study the potential implication of TMEM45A in
chemosensitivity, cisplatin-induced apoptosis was inves-
tigated in TMEM45A knockdown cells. In SQD9 cells,
after TMEM45A silencing using siRNA, the cells were
incubated with or without 100 μM of cisplatin in nor-
moxic or hypoxic conditions and the cleavage of two
effectors of apoptosis, PARP (Poly(ADP-ribose) poly-
merase) and caspase 3, was analyzed by western blot.
Figure 3a shows that the cleavage of the two effectors was
much higher in the inactivated cells compared to control
cells when incubated in the presence of cisplatin both in
normoxic and hypoxic conditions. In order to validate the
impact of TMEM45A inactivation on chemosensitivity,
TMEM45A expression was also silenced using shRNA. As
for siRNA, the cleavage of the two effectors was more
important in the TMEM45A-inactivated cells compared
to control cells (Fig. 3b) meaning that, when TMEM45A
was absent, SQD9 cells were more sensitive to cisplatin.
An increase in caspase 3/7 activity in the TMEM45A-
inactivated cells was also detected, which, however, did
not reach statistical significance (Fig. 3c). Furthermore,
the cytotoxicity of cisplatin was increased in cells inacti-
vated for TMEM45A (Fig. 3d). In order to confirm this
result, TMEM45A overexpression was performed.
TMEM45A overexpressing cells were more resistant to
cisplatin than control cells (Supplementary Fig. 6A). This
was also observed in another HNSCC cell line, Cal 27
(Supplementary Fig. 6B).
All together, these results showed that SQD9 cells were
more sensitive to cisplatin in the absence of TMEM45A
and indicated that this protein exerts a role in the resis-
tance of SDQ9 cells to this drug.
To confirm the role of TMEM45A in drug resistance,
we performed similar experiments in RCC4+ pVHL cells.
TMEM45A was knockdown using shRNA and the cells
were incubated with or without 20 μM of cisplatin for
48 h. Surprisingly, TMEM45A knockdown led to a sig-
nificant decrease in the cleavage of PARP and caspase 3
compared to control cells (Fig. 3e). To confirm this result,
cisplatin cytotoxicity was assessed. An increase in cyto-
toxicity and a decrease in cell viability were observed in
knockdown cells (Fig. 3f, g). RCC4+ pVHL cells were
thus more resistant to cisplatin when TMEM45A was
knockdown, meaning that, in this cell type, TMEM45A
exerts a pro-apoptotic role.
Effect of TMEM45A inactivation on cisplatin-induced DNA
damage
To identify by which mechanism TMEM45A plays a pro
or an anti-apoptotic role according to the cancer cell type,
we investigated the impact of cisplatin on DNA damage
response. The efficiency of this drug depends not only on
its ability to induce DNA damage but also on the cell
ability to detect and respond to these damages27. Indeed,
following DNA damage, cells may either repair the
damage or if they cannot repair, the damages activate cell
death by apoptosis. Histone H2AX (H2A Histone Family
Member X) is one of the markers for DNA double strand
breaks and allows, by its phophorylation (then named
γH2AX), the detection of DNA damage and the recruit-
ment of DNA damage repair proteins28. Thus, we inves-
tigated the detection and repair of DNA damage in the
two cell lines. SQD9 cells were incubated in the presence
of cisplatin for different durations and the abundance of
PARP fragment and of γH2AX was studied for apoptosis
and DNA damage detection respectively. Figure 4a shows
an increased level of γH2AX after 1, 2, and 4 h of treat-
ment but no difference was observed in knockdown cells
compared to control cells. These results suggest that
TMEM45A inactivation had no effect on the DNA
damage induction or detection. Furthermore, for these
(see figure on previous page)
Fig. 1 TMEM45A and CAIX expression in head and neck and renal cancers. a The expression level of TMEM45A was determined by RT-qPCR in
18 pairs of head and neck cancer biopsies and corresponding adjacent normal tissues. In the right panel, results are expressed as mean ± SD (n = 22).
b The expression level of TMEM45A was determined by RT-qPCR in 25 pairs of renal cancer and corresponding adjacent normal tissues. In the right
panel, results are expressed as mean ± SD (n = 25). c TCGA analysis of samples from human tumors (red) and corresponding healthy tissues (green).
ESCA esophageal carcinoma, HNSC head and neck squamous carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP
kidney renal papillary cell carcinoma. The number of samples is given between brackets, red labeling indicates a significant increase in TMEM45A
expression in two cancer types. The expression level of CAIX was determined by RTqPCR (d) in eight pairs of head and neck cancer biopsies
and corresponding adjacent normal tissues and (e) in ten pairs of renal cancer biopsies and corresponding adjacent normal tissues. **p < 0.01,
***p < 0.001.
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incubation times, the cleavage of PARP observed was very
low, suggesting that apoptosis was not yet activated.
Next, we explored DNA damage during recovery to
analyze repair ability. Cells were incubated in the presence
of cisplatin. The drug was thenremoved and cells were
incubated in fresh medium. After 4 h and 20 h of recovery,
γH2AX reappeared and was significantly increased in the
knockdown cells compared to control cells. The same
results were observed for PARP cleavage, suggesting that
SQD9 cells underwent apoptosis after 4 h and 20 h of
recovery (Fig. 4b). TMEM45A inactivation in SQD9 cells
using another shRNA led to similar results (Supplemen-
tary Fig. 7).
It has to be noted that γH2AX is also present at DNA
points breaks when DNA is fragmented during apopto-
sis29. So, a part of γH2AX observed was probably due to
apoptosis. There are several possibilities to explain these
results. First, even if cisplatin was removed from the
medium, the drug could be sequestrated inside the cells
and could continue to produce DNA damage. No differ-
ence in DNA damage induction or detection was
observed. Furthermore, we analyzed the phosphorylation
of ATM substrate. ATM is recruited and activated by
DNA double strand breaks and phosphorylates several
targets such as H2AX
30,31. Figure 4c shows no difference
in ATM/ATR substrate phosphorylation profile in the
knockdown cells compared to control cells. These results
confirm that TMEM45A inactivation did not impact the
induction or the recognition of DNA damage. The second
possibility is a decrease in the ability of the cells to evade
cisplatin-induced cell death for example via the regulation
of proteins involved in the apoptotic pathway. Indeed,
deregulation of the expression of repair protein encoding
genes was observed in the RNA-sequencing analysis
(Supplementary Fig. 3 and Fig. 4d). The third possibility is
a defect in DNA damage repair mechanism in the
knockdown cells, hence leading to cell death. In order to
confirm this hypothesis, we explored the possible role of
TMEM45A in the recruitment of DNA damage repair
proteins. RNA-sequencing data showed that EYA3 (Eyes
Absent Homolog 3) was differentially expressed in the
knockdown cells in the presence of cisplatin. EYA3 is
known to interact with γH2AX only under DNA damage
conditions. The phosphatase activity of EYA3 depho-
sphorylates γH2AX, leading to DNA damage repair and
cell survival32. EYA3 downregulation both at mRNA and
protein levels was observed when TMEM45A was
silenced (Fig. 4e, f). In addition, EYA3 expression was
assessed in head and neck cancer biopsies. The results
show that the expression profiles of TMEM45A and of
EYA3 were similar. Indeed, when TMEM45A was upre-
gulated EYA3 was also overexpressed and the only patient
who presented a downregulation of TMEM45A also dis-
played a downregulation of EYA3 (Supplementary Fig. 8).
These results suggest that TMEM45A silencing had an
impact on DNA damage repair through a lack of depho-
sphorylation of γH2AX by EYA3, hence inducing a
decrease in the recruitment of proteins involved in DNA
damage repair and, consequently, cell death.
To confirm the role of TMEM45A in DNA damage
repair, the recruitment of one of the major proteins
involved in DNA damage repair, RAD51 (RAD51
recombinase), was studied. γH2AX and RAD51 immu-
nofluorescence labeling showed a strong decrease in the
recruitment of RAD51 to DNA damage foci in
TMEM45A knockdown cells exposed to cisplatin. Fur-
thermore, the absence of RAD51 recruitment was asso-
ciated with the presence of γH2AX labeling meaning that
the DNA damage was still present and detected (Fig. 5).
These results indicate that the absence of TMEM45A
increased SQD9 cell chemosensitivity by decreasing
RAD51-associated DNA damage repair. All these
(see figure on previous page)
Fig. 2 Effect of TMEM45A inactivation on cell morphology and proliferation in SQD9 and RCC4 cells. SQD9 and RCC4 cells were transduced
with lentiviral particles expressing shRNA control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA22) or were not transduced (UT).
a SQD9 cell morphology was studied by optical microscopy (magnification ×200) and b transmission electron microscopy. c RCC4 cell
morphology was studied by optical microscopy (magnification ×200). d, e SQD9 cells were transduced with lentiviral particles expressing shRNA
control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA 22). The cells were incubated with or without 100 mM of cisplatin in normoxic
(N) conditions for 24 h and gene expression level was assessed by RNA sequencing. d Ten first genes differentially expressed in the knockdown
cells in the absence or in the presence of cisplatin. e The transcriptome analysis was performed using Babelomics and GSEA after RNA sequencing.
Heatmap of differentially expressed genes produced by using the heatmapper26 (http://www.heatmapper.ca) showed a potential deregulation of
the G2/M transition pathway. Genes have been reordered by the method of average clustering. A dendrogram is shown for the clustering of
genes. Genes with relatively high expression are marked in red, genes with relatively low expression are marked in blue. The corresponding values
are presented in Supplementary Fig. 4. f After the tranduction, SQD9 cells were incubated in normoxic conditions for 24 and 48 h then, the
proliferation was assessed by MTT assay. The signal intensity of the control cells at the seeding (time 0) was used to normalize the number of
viable cells at different time points. Results are expressed as mean ± SD (n = 3). **p < 0.01. g After the transduction, RCC4 cells were incubated in
normoxic conditions for 24, 48, and 72 h then, the proliferation was assessed by MTT assay. The signal intensity of the control cells at the seeding
(time 0) was used to normalize the number of viable cells at different time points. Results are expressed as mean ± SD (n = 3). N normoxia,
NC normoxia + cisplatin. **p < 0.01.
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experiments were repeated in RCC4+ pVHL cells but no
differences in DNA damage induction or repair were
observed (data not shown).
Effect of TMEM45A inactivation on cisplatin-induced UPR
activation
The transcriptome analysis also revealed a potential
deregulation of the unfolded protein response (UPR)
(Supplementary Fig. 3 and Fig. 6a). Based on the knowl-
edge that TMEM45A is localized to the trans-Golgi
apparatus and that protein modification pathways appears
to be altered in TMEM45A-knockdown cells (Supple-
mentary Fig. 9A), we decided to further investigate UPR.
The role of UPR activation in regulating cisplatin-
induced cell death is controversial. Indeed, some studies
showed that UPR activation led to resistance to cell death
induced by cisplatin33,34, while it has been shown that
cisplatin can induce apoptotic signaling via UPR activa-
tion, independently of DNA damage in enucleated cells35.
In fact, a moderate UPR activation is rather anti-
apoptotic. However, severe UPR activation leads to
apoptosis via the IRE1α (inositol-requiring enzyme-1) and
PERK (PRKR-Like Endoplasmic Reticulum Kinase) path-
way activation36. To study the effect of TMEM45A
knockdown on UPR activation, both cell lines were
incubated with 20 μM of cisplatin for 48 h. These condi-
tions were chosen since, at earlier time points, no UPR
activation could be detected (data not shown).
We first validated RNA-sequencing results using RT-
qPCR. For SQD9 cells, we confirmed the increase in the
expression of MANF (Mesencephalic Astrocyte Derived
Neurotrophic Factor), PDIA6 (Protein Disulfide
Isomerase-Associated 6), and HSP90B1 (Heat Shock
Protein 90 kDa Beta Member 1). ATF6B (Activating
Transcription Factor 6 Beta) and Calr (Calreticulin)
expression also showed the same tendency, but the sta-
tistical significance was not reached (Fig. 6b). On the
contrary, these genes did not show any deregulation in
RCC4+ pVHL cells (Fig. 6d).
In order to confirm UPR activation, we analyzed the
expression of total and phosphorylated forms of IRE1α. It
has to be noted that we did not succeed in detecting a
band corresponding to the phosphorylated protein in
SQD9 cells (data not shown). IRE1α activation was thus
analyzed through its unconventional RNA splicing activity
of XBP1 (X-box binding protein 1)37.
An increase in XBP1 splicing in the presence of cisplatin
was observed in both cell lines, confirming the activation
of the UPR pathway. More importantly, we observed a
significant increase in XBP1 splicing in TMEM45A-
knockdown SQD9 cells while this splicing was
decreased in TMEM45A-knockdown RCC4+ pVHL cells
(Fig. 6c, e). These results suggest that TMEM45A inac-
tivation has opposite effects on the cisplatin-induced UPR
activation in the two cell lines.
Discussion
In this study, we demonstrated that TMEM45A inacti-
vation impacted several functions. Very little is known
about this protein. RNA-sequencing analysis evidenced
several deregulated pathways associated with golgi appa-
ratus and endoplasmic reticulum. Furthermore, we
underlined the complex differential responses upon
TMEM45A inactivation according to the cancer cell type.
Among the deregulated pathways, a deregulation of
fatty acid biosynthesis (Supplementary Figs. 3 and 9b) was
detected. PTGS2 (Prostaglandin-Endoperoxide Synthase
2), PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and
ALOX5 (Arachidonate 5-Lipoxygenase) gene products are
localized in the endoplasmic reticulum. Metabolic adap-
tation of cancer cells is a complex process mainly char-
acterized by a switch of mitochondrial oxidative
phosphorylation to aerobic glycolysis38,39. However, some
studies highlighting the role of fatty acid metabolism in
(see figure on previous page)
Fig. 3 Effect of TMEM45A inactivation on the chemosensitivity to cisplatin in SQD9 and RCC4 cells. SQD9 cells were transfected with siRNA
control (siRF = risc free) or siRNA targeting the mRNA of TMEM45A (siTMEM45A). SQD9 cells were incubated with or without 100 mM of
cisplatin in normoxic (N) and hypoxic (H) conditions for 24 h. a The apoptosis was studied by western blot analyses of PARP and caspase 3
cleavage. Actin was used as the loading control. Results are expressed as mean ± SD (n = 3). b–d SQD9 cells were transduced with lentiviral
particles expressing shRNA control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA 22). SQD9 cells were incubated with or without
100 mM of cisplatin in normoxic (N) and hypoxic (H) conditions for 24 h. b After transduction and incubation, the cleavage of PARP and
caspase 3 was assessed by western blot. Actin was used as the loading control. Results are expressed as mean ± SD (n = 3). c After the
incubation, caspase 3 and 7 activity was assessed by measuring free AFC released from the cleavage of caspase 3 and 7 specific substrate Ac-
DEVD-AFC. Results are expressed as mean ± SD (n = 5). d The cytotoxicity of cisplatin was assessed by LDH release. Results are representative of
three biological replicates. e–g RCC4 cells were transduced with lentiviral particles expressing shRNA control (shCTL) or shRNA targeting the
mRNA of TMEM45A (shRNA 22). RCC4 cells were incubated with or without 20 mM of cisplatin in normoxic (N) or hypoxic (H) conditions for 48
h. e After transduction and incubation, the cleavage of PARP and caspase 3 was assessed by western blot. Actin was used as the loading
control. Results are expressed as mean ± SD (n = 3). f The cytotoxicity of cisplatin was assessed by LDH release. Results are expressed as mean
± SD (n = 3). g After the incubation, the number of viable cells was determined using MTT assay. The signal intensity of the control cells was
used for normalization a. Results re expressed as mean ± SD (n = 3). N normoxia, NC normoxia + cisplatin, H hypoxia, HC hypoxia + cisplatin.
*p < 0.05, **p < 0.01.
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cancer proliferation40–42. This result means that the
absence of TMEM45A in SQD9 cells may induce meta-
bolic changes.
In addition, our results showed an alteration of the pro-
tein modification pathway and of UPR indicating
that TMEM45A may be involved in post-translation protein
modification and cellular trafficking. Indeed, the
deregulation of ICMT (Isoprenylcysteine Carboxyl
Methyltransferase) and GALNT2 (Polypeptide N-Acet-
ylgalactosaminyltransferase 2) genes, which are implicated
in post-translational methylation and O-linked glycosyla-
tion, and of INSIG1 (Insulin Induced Gene 1), which
mediates protein feedback between endoplasmic reticulum
and golgi apparatus supports this hypothesis. These changes
possibly lead to the accumulation of unfolded proteins and
then to UPR basal activation in TMEM45A- knockdown
cells. Furthermore, upon cisplatin exposure, the basal acti-
vation induced by TMEM45A inactivation could modify the
response to cisplatin. Indeed, in the presence of cisplatin
SQD9 cells showed a severe activation of UPR pathway that
may lead to cell death whereas RCC4 cells showed a
moderate activation of UPR pathway that may confer
resistance to cisplatin-induced cell death33.
RNA-sequencing analysis also suggested that
TMEM45A silencing impacts SQD9 cell responses to
cisplatin through the deregulation of DNA damage
responses. DNA damage induce the accumulation of p53,
leading to the transcription of genes involved in cell cycle
checkpoints and in the intrinsic and extrinsic apoptosis
pathways43. However, p53 is mutated in SQD9 cells.
Hence, we investigated upstream events. In SQD9 cells,
we observed a decreased in EYA3 expression, which may
lead to a lack of dephosphorylation of γH2AX and a
decrease in RAD51 recruitment to DNA damage foci.
These data may explain the increased chemosensitivity
observed in SQD9 cells.
The absence of TMEM45A also led to a significant
decrease in cell proliferation as already shown in human
ovarian cancer cells and in human glioma cells17,18,
indicating that at least in four different cancer types, cell
proliferation is a pathway dependent on TMEM45A
expression. For the first time our work provides an
explanation for this observation. Indeed, the decrease in
proliferation observed in TMEM45A-inactivated cells
may be explained by the deregulation of the expression of
genes implicated in G2/M transition pathway such as
FANCA (Fanconi Anemia Complementation Group A)
and ARPP19 (CAMP Regulated Phosphoprotein 19).
FANCA is a DNA repair protein, which plays a role in the
cell cycle checkpoint and in the maintenance of chro-
mosome stability44. ARPP19 inactivates PP2A (Protein
Phosphatase 2) in order to keep cyclin B1-CDK1 activity
high during M phase45,46. The downregulation of these
two genes may explain the delay observed in the
TMEM45A-inactivated cell proliferation.
This study highlines for the first time the dual role of
TMEM45A in drug sensitivity depending of the cancer
type. Indeed, TMEM45A knockdown modulated
cisplatin-activation of UPR pathway, leading to the resis-
tance of RCC4+ pVHL cells, whereas it increased SQD9
cell sensitivity to cisplatin through the deregulation of cell
responses to cisplatin-induced DNA damage. Altogether,
these data emphasize the involvement of TMEM45A in
tumor aggressiveness and suggest that TMEM45A might
be a putative target to develop new chemosensitizing
agents at least in some cancer types.
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Fig. 4 Effect of TMEM45A inactivation on DNA damage induction and repair. SQD9 cells were transduced with lentiviral particles expressing
shRNA control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA 22). a SQD9 cells were incubated with or without 100 mM of cisplatin in
normoxic conditions for 15, 30 min, 1, 2, and 4 h. After the incubation, proteins were extracted and PARP cleavage and gH2AX protein level were
assessed by western blot. Actin was used as the loading control. Results are expressed as mean ± SD (n = 3). b SQD9 cells were incubated with or
without 100 mM of cisplatin in normoxic conditions for 4 h then the fresh medium without cisplatin was added to the cells for 4 or 20 h. After the
incubation, proteins were extracted and PARP cleavage and gH2AX protein level were assessed by western blot. Actin was used as the loading
control. Results are expressed as mean ± SD (n = 3). c SQD9 cells were incubated with or without 100 mM of cisplatin in normoxic conditions for 24
h. ATM/ATR substrate phosphorylation profile was assessed by western blot. Actin was used as loading control. Results are expressed as mean ± SD
(n = 3). d SQD9 cells were transduced with lentiviral particles expressing shRNA control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA
22). The cells were incubated with or without 100 mM of cisplatin in normoxic (N) conditions for 24 h and gene expression level was assessed by RNA
sequencing. The transcriptome analysis was performed using Babelomics and GSEA after RNA sequencing. Heatmap of differentially expressed genes
produced by using Heatmapper26 (http://www.heatmapper.ca) showed a potential deregulation of DNA damage and apoptosis activation. Genes
have been reordered by the method of average clustering. A dendrogram is shown for the clustering of genes. Genes with relatively high expression
are marked in red, genes with relatively low expression are marked in blue. The corresponding values are presented in Supplementary Fig. 4. e SQD9
cells were incubated with or without 100 mM of cisplatin in normoxic conditions for 24 h. The expression level of EYA3 was determined by RT-qPCR.
Results are expressed as mean ± SD (n = 3). f SQD9 cells were incubated with or without 100 mM of cisplatin in normoxic conditions for 24 h. EYA3
expression level was assessed by western blot. Actin was used as loading control. Results are expressed as mean ± SD (n = 3). N normoxia, NC
normoxia + cisplatin. **p < 0.01, ****p < 0.0001.
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Fig. 5 Effect of TMEM45A inactivation on the recruitment of RAD51 to DNA damage foci. SQD9 cells were transduced with lentiviral particles
expressing shRNA control (shCTL) or shRNA targeting the mRNA of TMEM45A (shRNA 22). SQD9 cells were incubated with or without 100 mM of
cisplatin in normoxic conditions for 4 h then fresh medium without cisplatin was added to the cells for 4 h. After the incubation, the recruitment of
RAD51 was studied by confocal microscopy using anti-RAD51 antibody and Alexa 488 anti-rabbit antibody and the abundance of gH2AX was studied
using anti-gH2AX antibody and Alexa 488 anti-rabbit antibody. The nucleus was detected with Hoechst. Scale bars: 50 μm. The RAD51 signal intensity
was quantified by Image J on more than 100 cells. Results are expressed as mean ± SD (n = 3). *p < 0.05.
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